Who
Fred E. Cohen
Director
Company insider
Files Form 4 as: Director, CareDx; Director, Intellia Therapeutics; Director and 10% owner, Kyverna Therapeutics; Director, UroGen Pharma; Director, Progyny; Director, Veracyte; Director, Genomic Health; Director and 10% owner, Tandem Diabetes Care.
In numbers
- Trades disclosed
- 269
- Buys
- 1
- Sells
- 9
- Bought
- $2.8M
- Sold
- $5.0M
- Companies
- 11
- Companies where not an officer
- 11
- First trade
- 25 May 2006
- Last trade
- 12 Jun 2026
- Last filed
- 16 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jun 2026filed 16 Jun 2026 | CDNA CareDxDiagnostics & Labs | SEC FORM 4 Code A | —9,795 at $0.00 | filing |
| 12 Jun 2026filed 16 Jun 2026 | CDNA CareDxDiagnostics & Labs | SEC FORM 4 Code A | —9,795 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —9,200 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,300 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —13,300 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —9,200 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | KYTX Kyverna TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,093 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | KYTX Kyverna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,582 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | KYTX Kyverna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,582 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | KYTX Kyverna TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,093 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Bought | $1.4M150,000 at $9.35 | filing |
| 5 Jan 2026filed 7 Jan 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Bought | $1.4M150,000 at $9.35 | filing |
| 13 Jun 2025filed 17 Jun 2025 | CDNA CareDxDiagnostics & Labs | SEC FORM 4 Code A | —12,103 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —11,450 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | KYTX Kyverna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,351 at $0.00 | filing |
| 29 May 2025filed 2 Jun 2025 | KYTX Kyverna TherapeuticsBiotechnology | SEC FORM 4 Code A | —16,634 at $0.00 | filing |
| 6 Aug 2024filed 8 Aug 2024 | URGN UroGen Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 14 Jun 2024filed 20 Jun 2024 | CDNA CareDxoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —16,048 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | CDNA CareDxoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —16,048 at $0.00 | filing |
News
Contrasting Intellia Therapeutics (NASDAQ:NTLA) and BeyondSpring (NASDAQ:BYSI)NTLA · tickerreport.com · 19 Oct 2026Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)NTLA · themarketsdaily.com · 19 Oct 2026Intellia Therapeutics Names New CMO To Oversee Clinical And Regulatory FunctionsNTLA · rttnews.com · 13 Oct 2026
0 headlines in the last 90 days name Fred E. Cohen; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.